Compare R & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | SYRE |
|---|---|---|
| Founded | 1933 | 2013 |
| Country | United States | United States |
| Employees | N/A | 112 |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | 1994 | 2015 |
| Metric | R | SYRE |
|---|---|---|
| Price | $243.68 | $73.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $238.56 | $85.08 |
| AVG Volume (30 Days) | 381.6K | ★ 927.8K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | $102.36 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $143.34 | $13.93 |
| 52 Week High | $259.00 | $78.80 |
| Indicator | R | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 57.09 |
| Support Level | $184.78 | $67.18 |
| Resistance Level | $259.00 | $76.16 |
| Average True Range (ATR) | 6.97 | 4.12 |
| MACD | -0.66 | -0.97 |
| Stochastic Oscillator | 86.34 | 62.77 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.